Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

For years, people living with obesity have been given the same basic advice: eat less, move more. But while this mantra may ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

Dr. David Geier joined Good morning Charleston Wednesday to break down a new study and talk about some of the myths surrounding a persons BMI and what measureme ...

Denmark: Following a recent World Health Organization (WHO) alert on semaglutide-containing medicines, Novo Nordisk has ...

The study analyzed data from 44,030 adults in the US who participated in the National Health and Nutrition Examination Survey ...

Understanding the link between obesity, fatty liver disease and kidney stones provides a new perspective on prevention and ...

More than 100 million Americans who qualify as overweight could see themselves tip into the obese category under newly ...